Adverse events reported in clinical trials
| Finkelstein et al10 | COPE study1 | CORE study2 | COPPS study11 | CORP study12 | |
| Gastrointestinal | NA* | 6.7 vs 8.3 | 14.0 vs 7.0 | 4.4 vs 8.9 | 5.0 vs 7.0 |
| Alopecia | NA | 0 vs 0 | 0 vs 0 | 0 vs 0 | 0 vs 0 |
| Anorexia | NA | 0 vs 0 | 0 vs 0 | 0 vs 0 | 0 vs 0 |
| Hepatotoxicity | NA | 0 vs 0 | 0 vs 0 | 0 vs 0 | 2.0 vs 0 |
| Myotoxicity | NA | 0 vs 0 | 0 vs 0 | 1 vs 0 | 0 vs 0 |
| Bone marrow toxicity | NA | 0 vs 0 | 0 vs 0 | 0 vs 0 | 0 vs 0 |
| Drug withdrawal | NA | 0.0 vs 8.3 | 0.0 vs 7.0 | 6.7 vs 11.7 | 7.0 vs 8.0% |
Data are reported as percentages with comparison placebo versus colchicine. For all comparison p values>0.05.
↵* 52 of 163 (31.9%) were excluded from analysis of outcomes for side effects or other complications.
NA, not available.